Alkem Laboratories Limited
ALKEM
Rank in Stocks
#2814
Alkem Laboratories Ltd. functions as a pharmaceutical enterprise, engaged in... Alkem Laboratories Ltd. functions as a pharmaceutical enterprise, engaged in the research, manufacturing, and worldwide distribution of both medicinal and nutritional products. Its comprehensive offerings encompass a variety of branded and generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and nutraceuticals. These products target both immediate and chronic health issues across numerous therapeutic areas, including anti-infectives, skin conditions, cardiovascular health, respiratory ailments, digestive problems, central nervous system disorders, cancer, urology, and women's health. The company also provides essential vitamins, minerals, and nutritional supplements, in addition to pain relief medications, anti-diabetic treatments, and neurological remedies. Complementing its core pharmaceutical lines, Alkem offers consumer health items such as pregnancy detection kits and condoms. Founded in 1973, the company's headquarters are located in Mumbai, India.
Share Price
$55.19
Market Cap
$6.60B
Change (1 day)
-0.06%
Change (1 year)
-12.43%
Country
IN
Trade Alkem Laboratories Limited (ALKEM)
Category
Healthcare
P/E ratio for Alkem Laboratories Limited (ALKEM)
P/E ratio as of October 2026 TTM: 28.72
According to Alkem Laboratories Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 28.72. At the end of 2024 the company had a P/E ratio of 33.35.
P/E ratio history for Alkem Laboratories Limited from 2010 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 28.72 | 7.58% |
| 2025 | 26.70 | -19.94% |
| 2024 | 33.35 | -19.17% |
| 2023 | 41.26 | 56.84% |
| 2022 | 26.31 | 25.91% |
| 2021 | 20.89 | -15.32% |
| 2020 | 24.67 | -10.19% |
| 2019 | 27.47 | -24.47% |
| 2018 | 36.37 | 23.08% |
| 2017 | 29.55 | 35.14% |
| 2016 | 21.87 | -48.16% |
| 2015 | 42.19 | 12.11% |
| 2014 | 37.63 | 13.01% |
| 2013 | 33.30 | -14.24% |
| 2012 | 38.83 | -23.99% |
| 2011 | 51.08 | -27.33% |
| 2010 | 70.29 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 21.71% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.